Get the Stockscreener App
354.47
1.24%
4.34
Beone Medicines Ltd Adr stock is traded at $354.47, with a volume of 191.32K.
It is up +1.24% in the last 24 hours and up +0.99% over the past month.
Formerly known as BeiGene and founded in 2010 in Beijing, BeOne is a commercial-stage biotech firm that produces oncology therapeutics. The company's main product is Brukinsa, which is a small-molecule drug that treats multiple forms of Non-Hodgkin lymphoma and leukemia. The company conducts drug discovery, runs global clinical trials, and manufactures drugs independently. As of 2025, Brukinsa made up for 74% of total revenue, while it has two other approved commercialized drugs in its portfolio, Beqalzi and Tevimbra. While Brukinsa has a global leadership, the other two drugs generate revenue mostly from China. Based on Brukinsa, BeOne competes with AbbVie and AstraZeneca mainly. The company also has more than 50 drugs in clinical trials in its active pipeline, focused on other cancers.
See More
Previous Close:
$350.13
Open:
$348
24h Volume:
191.32K
Relative Volume:
0.57
Market Cap:
$40.10B
Revenue:
$5.76B
Net Income/Loss:
$514.49M
P/E Ratio:
79.10
EPS:
4.4813
Net Cash Flow:
$1.10B
1W Performance:
-1.01%
1M Performance:
+0.99%
6M Performance:
+13.10%
1Y Performance:
+5.56%
1-Day Range:
$347.72
$357.14
1-Week Range:
$340.44
$368.40
52-Week Range:
$253.95
$385.22
Beone Medicines Ltd Adr Stock (ONC) Company Profile
Name
Beone Medicines Ltd Adr
Sector
Industry
Phone
41-616851900
Address
C/O BEONE MEDICINES I GMBH, BASEL
Compare ONC vs VRTX, MRNA, REGN, ARGX, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ONC
Beone Medicines Ltd Adr
|
354.47 | 40.10B | 5.76B | 514.49M | 1.10B | 4.4813 |
VRTX
Vertex Pharmaceuticals Inc
|
510.08 | 129.29B | 12.34B | 4.34B | 3.71B | 16.87 |
MRNA
Moderna Inc
|
225.00 | 89.83B | 2.23B | -3.19B | -1.60B | -8.1462 |
REGN
Regeneron Pharmaceuticals Inc
|
746.54 | 76.86B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
825.03 | 51.88B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
189.76 | 40.67B | 742.00K | -1.37B | -1.07B | -7.0731 |
Beone Medicines Ltd Adr Stock (ONC) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-13-26 | Upgrade | Jefferies | Hold → Buy |
| Mar-27-26 | Initiated | Wolfe Research | Outperform |
| Mar-16-26 | Downgrade | Jefferies | Buy → Hold |
| Nov-24-25 | Initiated | Truist | Buy |
| Sep-18-25 | Initiated | Barclays | Overweight |
| Apr-07-25 | Initiated | RBC Capital Mkts | Outperform |
| Mar-03-25 | Upgrade | BofA Securities | Neutral → Buy |
| Dec-03-24 | Resumed | Morgan Stanley | Overweight |
| Sep-18-24 | Initiated | JMP Securities | Mkt Outperform |
| Feb-06-24 | Resumed | JP Morgan | Overweight |
| Sep-12-23 | Initiated | Macquarie | Outperform |
| Aug-17-23 | Initiated | Jefferies | Buy |
| Jul-17-23 | Initiated | Citigroup | Buy |
| Jun-30-23 | Downgrade | Bernstein | Outperform → Mkt Perform |
| Jan-12-23 | Initiated | Daiwa Securities | Buy |
| Oct-13-22 | Upgrade | Guggenheim | Neutral → Buy |
| Oct-13-22 | Upgrade | SVB Leerink | Mkt Perform → Outperform |
| Aug-09-22 | Resumed | JP Morgan | Overweight |
| Mar-17-22 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| Feb-07-22 | Initiated | Deutsche Bank | Buy |
| Oct-12-21 | Initiated | Bernstein | Outperform |
| Oct-06-21 | Upgrade | CLSA | Underperform → Buy |
| Mar-08-21 | Initiated | China Renaissance | Buy |
| Mar-01-21 | Downgrade | CLSA | Outperform → Underperform |
| Nov-09-20 | Downgrade | Ladenburg Thalmann | Buy → Neutral |
| Nov-06-20 | Downgrade | Maxim Group | Buy → Hold |
| Nov-06-20 | Downgrade | Piper Sandler | Neutral → Underweight |
View All
Beone Medicines Ltd Adr Stock (ONC) Latest News
Form 4 BeOne Medicines Ltd. For: 1 October By Investing.com - Investing.com Canada
Form 4 BeOne Medicines Ltd. For: 1 October By Investing.com - Investing.com Nigeria
Form 4 BeOne Medicines Ltd. For: 1 October - Investing.com India
After exercising options, BeOne Medicines (ONC) scientific advisory chair sold 31,028 depositary shares. - Stock Titan
ONC Q2 2026 Earnings: Reported EPS of $13.84 as Shares Edge LowerEarnings Volatility Report - dars.gov.et
BeOne Medicines (ONC) insiders exercise options for 30,768 ADS - Stock Titan
BeOne Medicines (ONC) backer Baker Bros. funds $1.1M employee ADS option exercise - Stock Titan
Engineers Gate Manager LP Acquires New Position in BeOne Medicines Ltd.Sponsored ADR $ONC - MarketBeat
Xiaodong Wang Sells 38,287 Shares of BeOne Medicines (NASDAQ:ONC) Stock - MarketBeat
BeOne Medicines (ONC) director trades ADS under preset plan - Stock Titan
Squarepoint Ops LLC Boosts Stock Position in BeOne Medicines Ltd.Sponsored ADR $ONC - MarketBeat
Baird Financial Group Inc. Raises Position in BeOne Medicines Ltd.Sponsored ADR $ONC - MarketBeat
Nykredit A S Invests $1.20 Million in BeOne Medicines Ltd.Sponsored ADR $ONC - MarketBeat
Public Employees Retirement System of Ohio Invests $2.14 Million in BeOne Medicines Ltd.Sponsored ADR $ONC - MarketBeat
BeOne Medicines Ltd.Sponsored ADR (NASDAQ:ONC) Receives Average Recommendation of "Buy" from Brokerages - MarketBeat
B. Metzler seel. Sohn & Co. AG Has $1.91 Million Stock Position in BeOne Medicines Ltd.Sponsored ADR $ONC - MarketBeat
BeOne Medicines (NASDAQ:ONC) Insider Sells $46,973.52 in Stock - MarketBeat
BeOne Medicines (ONC) Holds Steady Near $362 Within Defined Trading RangeSmart Money Flow Stocks - careplusvn.com
BeOne Medicines (ONC) Holds Steady Near $362 Within Defined Trading RangeBPI Bear Correction - siam.in
BeOne (ONC) accounting chief sells ADS to cover RSU taxes - Stock Titan
BeOne Medicines (ONC) Holds Steady Near $362 Within Defined Trading RangeHigh Volume Node - dars.gov.et
BeOne Medicines (NASDAQ: ONC) insider to sell 132 ADS after vesting - Stock Titan
BeOne Medicines Ltd.Sponsored ADR (ONC) is a Great Momentum Stock: Should You Buy? - Yahoo Finance
BeOne Medicines COO Wu Xiaobin Executes ADS Sale Under Rule 10b5-1 Trading Plan - Kalkine Media
BeOne Medicines Ltd.Sponsored ADR (ONC) Now Trades Above Golden Cross: Time to Buy? - Yahoo Finance
BeOne Medicines (NASDAQ: ONC) ex-director lines up $788K ADS sale - Stock Titan
BeOne Medicines stock rises nearly 4% as buyers control session amid bullish technicals - Traders Union
BeOne Medicines (ONC) Secures Rights To Four RAS(ON) Inhibitors In Asia - Sahm
BeOne Medicines (NASDAQ:ONC) SVP Sells 2,666 Shares of Stock - MarketBeat
Insider Selling: BeOne Medicines (NASDAQ:ONC) CEO Sells $25,661,243.30 in Stock - MarketBeat
BeOne Medicines (NASDAQ:ONC) CEO Sells $19,659,569.80 in Stock - MarketBeat
BeOne Medicines Ltd.Sponsored ADR (NASDAQ:ONC) Given Average Recommendation of "Buy" by Brokerages - MarketBeat
Generali Investments Management Co LLC Buys Shares of 8,000 BeOne Medicines Ltd.Sponsored ADR $ONC - MarketBeat
The Manufacturers Life Insurance Company Trims Stake in BeOne Medicines Ltd.Sponsored ADR $ONC - MarketBeat
Charles Schwab Trust Co Acquires New Position in BeOne Medicines Ltd.Sponsored ADR $ONC - MarketBeat
BeOne Medicines (NASDAQ:ONC) Sees Unusually-High Trading VolumeStill a Buy? - MarketBeat
ONC Q2 2026 Earnings: EPS of $13.84 Signals Strong Quarter as Shares Rise 3.08%Earnings Cycle Report - dars.gov.et
Dimensional Fund Advisors LP Raises Position in BeOne Medicines Ltd.Sponsored ADR $ONC - MarketBeat
BeOne Medicines shares gain about 5.5% after robust Q2 results and new Phase 3 trials announcement - Traders Union
BeOne Medicines Ltd.Sponsored ADR $ONC Shares Bought by Bank of America Corp DE - MarketBeat
BeOne Medicines Q2 Earnings Call Highlights - sharewise.com
BeOne Medicines (NASDAQ:ONC) CFO Sells $361,805.47 in Stock - MarketBeat
BeOne Medicines (ONC) Advances 2.78% to $332.0, Approaching Key Resistance at $348.6Stock Surge Alerts - dars.gov.et
BeOne Medicines Ltd.Sponsored ADR (ONC) Q2 Earnings: How Key Metrics Compare to Wall Street Estimates - Yahoo Finance
BeOne Medicines (ONC) Advances 2.01% as Stock Holds Above Key SupportStandard Deviation - careplusvn.com
BeOne Medicines (ONC) Advances 2.78% to $332.0, Approaching Key Resistance at $348.6Watchlist Stock Ideas - careplusvn.com
BeOne Medicines (ONC) Advances 2.01% as Stock Holds Above Key SupportDescending Triangle - dars.gov.et
BeOne Medicines (ONC) Advances 2.78% to $332.0, Approaching Key Resistance at $348.6Fibonacci Retracement - dars.gov.et
BeOne Medicines Q2 Adjusted Earnings, Revenue Rise; Raises 2026 Revenue Guidance - Yahoo Finance
BeOne Medicines (ONC) Advances 2.01% as Stock Holds Above Key SupportFund Manager Survey - dars.gov.et
Beone Medicines Ltd Adr Stock (ONC) Financials Data
Revenue
Net Income
Cash Flow
EPS
Beone Medicines Ltd Adr Stock (ONC) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| CHAN LEE | Officer |
Sep 30 '26 |
Proposed Sale |
365.27 |
1,115 |
407,276 |
0 |
| Wang Xiaodong | Chair, Scientific Advisory Brd |
Sep 28 '26 |
Option Exercise |
36.90 |
31,028 |
1,144,933 |
31,028 |
| Wang Xiaodong | Chair, Scientific Advisory Brd |
Sep 28 '26 |
Sale |
364.79 |
31,028 |
11,318,558 |
0 |
| Wang Xiaodong | Chair, Scientific Advisory Brd |
Sep 08 '26 |
Sale |
349.10 |
38,287 |
13,366,092 |
0 |
| Wang Xiaodong | Chair, Scientific Advisory Brd |
Sep 08 '26 |
Option Exercise |
36.90 |
31,027 |
1,144,896 |
31,027 |
| XIAODONG WANG | Director |
Sep 08 '26 |
Proposed Sale |
358.26 |
131,370 |
47,064,616 |
0 |
| Ball Titus B. | Principal Accounting Officer |
Sep 01 '26 |
Sale |
355.86 |
132 |
46,974 |
0 |
| TITUS BENJAMIN BALL | Officer |
Sep 01 '26 |
Proposed Sale |
355.86 |
132 |
46,974 |
0 |
| Wu Xiaobin | President and COO |
Aug 25 '26 |
Sale |
380.00 |
280 |
106,400 |
0 |
| CORAZON D. SANDERS | Former Director |
Aug 25 '26 |
Proposed Sale |
380.00 |
2,075 |
788,500 |
0 |
0.87%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):